# X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

> **NCT02823405** · PHASE1 · COMPLETED · sponsor: **X4 Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** X4P-001
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02823405
- **Lead sponsor:** X4 Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-15
- **Primary completion:** 2018-03-15
- **Final completion:** 2018-03-15
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02823405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02823405, "X4P-001 and Pembrolizumab in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02823405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*